Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?

(NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every level of the biotech's operations, and the implications could perhaps be significant for investors. If the lofty claims made by others in the biotech industry are true, the company could see a smattering of benefits that ultimately enable it to capture more earnings. And, at a time when its coronavirus vaccine revenue is no longer enough to make the stock as appealing as it once was, Moderna shareholders are doubtless eager for good news.

But will this collaboration live up to the potential that others have theorized? Let's look at a few of the details to find out.

So far, Moderna has used different iterations of OpenAI's ChatGPT for a plethora of different purposes internally, and as much as 80% of employees use it. Supposedly there are more than 750 customized "GPTs" running in its internal ecosystem, which could indicate that many employees are using more than one AI tool every day. The most important task being handled right now uses a custom GPT called Dose ID GPT to help researchers select the appropriate vaccine dose for advancing into clinical trials.

Continue reading

Source Fool.com